Nima Farzan - 03 Apr 2024 Form 4 Insider Report for Kinnate Biopharma Inc.

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: N/A
Reported as of: 03 Apr 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Apr 2024, 16:55:41 UTC
Prior SEC filing: 08 Jun 2023
Next SEC filing: 03 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ James P. Reilly, Attorney-in-Fact

Key filing fact

Nima Farzan filed Form 4 for Kinnate Biopharma Inc. on 05 Apr 2024.

Key facts

This page summarizes Nima Farzan's Form 4 filing for Kinnate Biopharma Inc..
6 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 05 Apr 2024, 16:55.

Change

Previous filing in this sequence was filed on 08 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KNTE transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -2,186
Change %: -100%
Price
Shares after: 0
Date: 03 Apr 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNTE transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -1,281,642
Change %: -100%
Price
Shares after: 0
Date: 03 Apr 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,281,642
Exercise price: $2.57
Footnotes: F2

KNTE transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -437,413
Change %: -100%
Price
Shares after: 0
Date: 03 Apr 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 437,413
Exercise price: $5.63
Footnotes: F3

KNTE transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -275,000
Change %: -100%
Price
Shares after: 0
Date: 03 Apr 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 275,000
Exercise price: $35.38
Footnotes: F3

KNTE transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -400,000
Change %: -100%
Price
Shares after: 0
Date: 03 Apr 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price: $10.03
Footnotes: F3

KNTE transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -750,000
Change %: -100%
Price
Shares after: 0
Date: 03 Apr 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 750,000
Exercise price: $6.78
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Nima Farzan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR.

Footnote F2

This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option.

Footnote F3

This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.